BIND Therapeutics, Roche Enter Research Deal To Discover Novel Nanomedicines

(RTTNews) - BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, has reached a research agreement with Roche to discover novel nanomedicines using Accurins to treat diseases in therapeutic areas outside of oncology. The collaboration would conentrate on combining BIND's Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands.

Scott Minick, Chief Executive of BIND Therapeutics, stated: "By combining BIND's Medicinal Nanoengineering® platform with Roche's deep expertise in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas."